TYRATyra Biosciences, Inc.

Healthcare
$19.91+59% 1Y

The financials

Tyra Biosciences, Inc. by the numbers

The next results filing is expected around Nov 4, 2026, the same week as a year ago.

Tyra Biosciences, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$49M−$31Mn/a
Net income−$46M−$28Mn/a
Diluted EPS−$0.69−$0.47n/a
On our screens:Most shorted stocks

Biotechnology

Ranks #154 of 196 by RyuScore

Compare peers
GLUE-0.05%
Monte Rosa Therapeutics, Inc.
RAPP+2.9%
Rapport Therapeutics, Inc.
MESO+3.9%
Mesoblast Limited
IOVA+9.6%
Iovance Biotherapeutics, Inc.
STOK+3.3%
Stoke Therapeutics, Inc.
LKFT+0.78%
Lakefront Biotherapeutics NV